BioMarin Pharmaceutical (HAM:BM8) Valuation Rank


HAM:BM8 BioMarin Pharmaceutical Inc HAM:BM8
75 GF Score
Price €52.24
GF Value €77.85
! 3 Warning Signs
View Full Analysis

What is BioMarin Pharmaceutical Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

BioMarin Pharmaceutical Valuation Rank Related Terms

HAM:BM8
75GF Score
BioMarin Pharmaceutical Inc HAM:BM8
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is BioMarin Pharmaceutical (HAM:BM8) Overvalued in 2026?

Based on GuruFocus' analysis, BioMarin Pharmaceutical stock appears to be undervalued. The current stock price of €52.24 is trading 32.9% below its estimated GF Value™ of €77.85.

Key valuation signals for HAM:BM8:

  • Valuation Rank:
  • GF Value™: €77.85 vs. price of €52.24 (32.9% below fair value)
  • GF Score™: 75/100 with 3 warning signs

No single metric tells the full story. See the HAM:BM8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioMarin Pharmaceutical Business Description

Address 770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
75GF Score

Get the complete analysis for HAM:BM8

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€52.24
Price
€77.85
GF Value